PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast - Rebecca S. Heist, MD, MPH / Jacob Sands, MD - It’s Precisely the Time for More Precision in Genomic Testing and Targeted Treatment of NSCLC

Rebecca S. Heist, MD, MPH / Jacob Sands, MD - It’s Precisely the Time for More Precision in Genomic Testing and Targeted Treatment of NSCLC

08/04/20 • 60 min

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast

Go online to PeerView.com/NEN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, oncology experts discuss the roles of genomic testing and targeted treatment in lung cancer. Practical guidance for expanding molecular testing for genomic alterations occurring in non–small cell lung cancer with FDA-approved targeted therapies is explored. Upon completion of this activity, participants will be able to: Discuss the expanding role and increasing importance of broad genomic testing to identify molecular alterations that can guide the selection of matched targeted therapies for patients with NSCLC in the era of precision oncology, Describe new, emerging, and/or rare molecular alterations (eg, fusions, mutations, etc.) that are clinically relevant and therapeutically targetable in NSCLC, including NTRK, RET, MET, HER2, ROS1, KRAS, NRG1, and others, and the latest testing methods/tools for identifying these alterations, Analyze data from clinical trials of precision therapies that target molecular alterations such as NTRK, RET, ROS1, and NRG1 fusions, MET and KRAS G12C mutations, HER2 mutations or overexpression, EGFR exon 20 insertions, and others in advanced NSCLC, Implement best practices and collaborative strategies for integration of wide-spread molecular testing and interpretation of results into oncology and pathology workflows in community and academic settings to ensure that appropriate patients with NSCLC with genomic alterations are identified and receive the most appropriate therapies in the context of clinical practice or clinical trials.

Previous Episode

undefined - Sagar Lonial, MD, FACP - How I Think, How I Treat: Understanding Innovation in Multiple Myeloma—New Models for Attacking Disease Across the Clinical Spectrum

Sagar Lonial, MD, FACP - How I Think, How I Treat: Understanding Innovation in Multiple Myeloma—New Models for Attacking Disease Across the Clinical Spectrum

Go online to PeerView.com/XBQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert panel charts progress in myeloma care by discussing their personal experiences and insights, including analyses of how current evidence has informed the experts’ own practice along the disease continuum, from newly diagnosed to relapsed disease. This unique activity provides a link that connects novel agents to their applications in daily practice and clearly shows how novel antibodies, immunotherapy, and other innovative strategies have shaped a new model for myeloma care. Upon completion of this activity, participants should be better able to: Discuss updated practice guidelines and new efficacy and safety findings on the use of novel immunomodulating agents, proteasome inhibitors, antibodies, cell therapy, and targeted agents in the myeloma setting, Integrate novel therapeutics into the management of newly diagnosed myeloma, including for patients with smoldering disease or those with symptomatic disease regardless of transplant eligibility, Develop safe, personalized therapeutic platforms for patients with pretreated myeloma, including patients with an early relapse or those with heavily pretreated disease, Manage therapeutic safety, dosing, and monitoring considerations with novel treatment platforms in multiple myeloma.

Next Episode

undefined - Alok A. Khorana, MD, FACP, FASCO - Teaming Up to Reduce the Burden of Cancer-Associated VTE: Applying the Latest Guidelines and Evidence in Gastrointestinal and Hematologic Malignancies and Other Cancer Settings

Alok A. Khorana, MD, FACP, FASCO - Teaming Up to Reduce the Burden of Cancer-Associated VTE: Applying the Latest Guidelines and Evidence in Gastrointestinal and Hematologic Malignancies and Other Cancer Settings

Go online to PeerView.com/XDU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. A panel of hematology-oncology experts use the latest guidelines and real-world evidence to explore how the data have influenced clinical decision-making in cancer-associated VTE in different cancer settings. Using clinical scenarios and cases designed to build consensus, the experts illustrate how DOACs can be used to optimally integrate and implement evidence-based strategies for the prevention and treatment of cancer-associated VTE. Upon completion of this activity, participants will be able to: Review major patient- and treatment-related risk factors for cancer-associated VTE using established diagnostic tools to identify patients for initial treatment or thromboprophylaxis, Evaluate current evidence and guidelines for prevention and treatment of cancer-associated VTE in routine clinical practice, Select a safe and effective anticoagulation regimen including DOACs as initial VTE therapy and/or thromboprophylaxis for managing VTE in patients with gastrointestinal, hematologic, and other malignancies.